Journal of medical economicsHumansDermatitisAtopicCost-Benefit AnalysisAntibodies
Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in Taiwan.
Rachel Ai-Ting Yang, Valerie Tzu-Ning Liu, David Bin-Chia Wu, Toby Kai-Bo Shen, Hsiao-Hsiao Tan, Yen Hsiang Wang, John Tayu Lee
Published: 202610.1080/13696998.2026.2612867
Abstract
BACKGOROUND: Atopic dermatitis (AD), a chronic inflammatory skin disease, affects 1.28% of Taiwan's population, with 26.69% having moderate-to-severe cases, causing significant healthcare costs and quality-of-life impairments. Conventional treatments…
Preview only. Read the full abstract at the source